Can I Stay on a GLP-1 After Reaching My Goal Weight?
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Yes, in most cases you can stay on a GLP-1 medication after reaching your goal weight, because clinical guidelines now treat obesity as a chronic condition that benefits from long-term management, which means a licensed provider can evaluate you on your full picture (medical history, qualifying conditions, treatment history) rather than just your current BMI (American Association of Clinical Endocrinology, 2025 Algorithm for Adults with Obesity).
If you have done the hard work of losing weight and the question on your mind is whether anyone will keep prescribing for you now that your BMI is lower, you are not the only one asking. This shows up all the time in patient conversations, in three pretty common shapes. Some people have an active prescription somewhere and want to move it to a new provider. Some people have been finishing the last of an old fill and need to restock the right way. And some people took a break for a few months and want to start again. All three are normal situations, and a fresh evaluation with a licensed provider is the right move for any of them.
This article is a friendly tour of what that evaluation actually looks like, what the FDA labels really say, how Medicare and private insurance handle people who are already on the medication and now have a lower BMI, and what to bring with you to your appointment so you walk in ready. It is not medical advice, and every prescription decision belongs in a one-on-one conversation with the provider who knows your case.
Who This Helps
This one is for you if you take a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound, or a compounded GLP-1 product from a licensed pharmacy, and you have lost enough weight that your BMI is now below the original threshold you started at, if you are looking to switch providers and you worry a new clinician will not approve you, or if you have been off the medication for a stretch and want to start again.
What the FDA Labels Actually Say (and Do Not Say)
The starting point for any evaluation is the FDA-approved indication, which is the official description of who the medication was studied and approved for.
Wegovy is FDA-approved for adults with a BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) when at least one weight-related health condition is present, such as type 2 diabetes, high blood pressure, or high cholesterol (Wegovy Prescribing Information). In March 2024, the FDA also approved Wegovy to reduce the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease who are overweight or obese, which created a separate, second use that is independent of weight loss goals (FDA Press Announcement, First Treatment to Reduce Heart Risk in Adults with Obesity or Overweight).
Zepbound is FDA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition (Zepbound Prescribing Information). In December 2024, Zepbound also received FDA approval for adults with moderate-to-severe obstructive sleep apnea and obesity, which gave tirzepatide a second use tied to a specific medical condition rather than weight loss progress (FDA, First Medication for Obstructive Sleep Apnea).
The labels also have an important silence. They define who can start treatment, and they do not specifically require that a patient remain at a BMI of 27 or higher for the entire duration of treatment to stay on the medication. That difference matters, because clinical judgment about continuation lives in the space between the starting criteria and what happens over the months and years that follow.
Why Clinicians Often Continue Treatment Past Goal Weight
The clinical case for continuing GLP-1 treatment after a patient reaches a healthy weight rests on three findings in the published research.
Obesity is now understood and treated as a chronic disease. The American Association of Clinical Endocrinology’s 2025 algorithm for adults with obesity uses the term adiposity-based chronic disease, which is the medical framing for obesity as an ongoing condition that requires long-term care rather than a one-time fix, and the guideline supports prescribing weight management medications with the intent of long-term use when clinically appropriate (AACE 2025 Algorithm). That framing matters, because it shifts the question from “have you reached your goal” to “is the medication still helping you manage a chronic condition.”
Stopping GLP-1 treatment after weight loss is associated with weight coming back. The STEP 4 trial published in JAMA took adults who had already lost weight on semaglutide and randomly assigned them to either continue the medication or switch to placebo (an inactive shot). Over the next 48 weeks, the people who continued semaglutide lost an additional 7.9% of body weight, while those who switched to placebo regained 6.9% of body weight (JAMA, STEP 4 Randomized Clinical Trial). The regain on placebo was not a small effect.
Cardiovascular benefit appears to continue regardless of how much weight a patient has lost. The SELECT trial enrolled 17,604 adults with preexisting cardiovascular disease and a BMI of 27 or greater, without diabetes. Over the trial, semaglutide reduced the rate of major cardiovascular events by 20% compared with placebo (New England Journal of Medicine, SELECT Trial). This is part of why the FDA expanded the Wegovy label in 2024 to include cardiovascular risk reduction.
What this means in practice is that a clinician evaluating you for continuation has real clinical reasoning to support a prescription even after your weight has dropped, especially if any of the qualifying medical conditions are still part of your picture.
Insurance Coverage: Medicare and Private Insurance
The clinical case is one half of the picture. Insurance coverage is the other half, and it works differently depending on where your coverage comes from.
Medicare and the New $50 Bridge Program
If you are on Medicare, the big news is the Medicare GLP-1 Bridge, a CMS demonstration program (a time-limited pilot that lets Medicare test new coverage pathways) running from July 1, 2026 through December 31, 2027. The program lets eligible Medicare Part D beneficiaries get certain GLP-1 medications, including Wegovy and Zepbound, for a flat $50 monthly copay (CMS, Medicare GLP-1 Bridge).
The most important detail for anyone already on a GLP-1 is that the Bridge program is explicitly built to cover people who started treatment before the program launched. Eligibility for continuing patients is based on whether you met the clinical criteria at the time your therapy was initiated, not your current BMI. A CMS-provided example walks through this directly: a person who began GLP-1 therapy in September 2024 with a BMI of 37 and now has a BMI of 34 at the time of a July 2026 prior authorization request can still qualify, because the prescribing provider can attest that the person met the BMI of 35 or higher criterion when treatment originally started (CMS, Medicare GLP-1 Bridge).
To qualify, a patient must meet one of three clinical pathways at the time their GLP-1 therapy was initiated:
- BMI of 35 or greater, on its own
- BMI of 30 or greater, plus a diagnosis of heart failure, uncontrolled high blood pressure, or moderate to advanced kidney disease
- BMI of 27 or greater, plus a diagnosis of prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease (which means circulation problems in the limbs that cause symptoms like cramping or pain when walking)
If you started your GLP-1 with one of these criteria in place, you can likely keep your access through the Bridge even if your current numbers are now better. Your prescribing provider’s attestation about your numbers at the time of starting treatment is what carries the weight here.
Outside of the Bridge program, Medicare’s coverage of GLP-1 medications is narrower. Federal law has historically excluded medications prescribed solely for weight loss from Medicare Part D. The Wegovy cardiovascular indication approved in March 2024 made it permissible for individual Medicare Part D plans to cover Wegovy specifically for the cardiovascular risk reduction use case in adults with established cardiovascular disease, but Part D plans are not required to add Wegovy to their formularies, and many have not (KFF, A New Use for Wegovy Opens the Door to Medicare Coverage). Where it is covered, it usually requires prior authorization with documentation of the cardiovascular diagnosis, and it often sits on a specialty pricing tier rather than at a flat copay. The GLP Winner article What Medicare’s $50 GLP-1 Plan Actually Means for You walks through how to think about the Bridge program for your situation.
Private Insurance
Private insurance plans set their own coverage rules, called formularies. Many plans cover GLP-1 medications for weight loss but require prior authorization, which is documentation from your prescribing clinician showing that you meet the plan’s specific criteria. Those criteria often mirror the FDA-approved starting criteria (a BMI of 30 or 27 with a weight-related condition), and some plans also require ongoing documentation of continued progress or qualifying conditions.
If you have lost enough weight that your BMI is now below 27, some plans will not renew coverage. Others will keep coverage going if your clinician documents that the medication is now serving a maintenance role, that you have an ongoing qualifying condition like cardiovascular disease or type 2 diabetes, or that the risk of weight coming back if you stop is medically significant in your case.
Coverage rules also change year over year, so a plan that did not cover continuation last year may add that pathway in the new plan year.
Compounded vs FDA-Approved: How the Evaluation Differs
The licensed-provider evaluation requirement applies to both pathways. The differences live in how each pathway operates.
For FDA-approved brands, the evaluation typically follows the FDA-approved indication closely. A clinician verifies that you meet the starting criteria (or now, the continuation criteria) and submits prior authorization to your insurance plan if coverage applies. Documentation tends to focus on BMI, weight history, and qualifying conditions because those are the levers insurance approval turns on.
Compounded GLP-1 products from licensed 503A and 503B pharmacies are prescribed by licensed practitioners for individual patient needs based on a valid prescription, which means a real clinical evaluation by your prescribing provider is required before any prescription is written (FDA, Compounding and the FDA Questions and Answers). That evaluation typically covers your medical history, current weight and health status, medications, and any contraindications, much like a brand-name evaluation. Because compounded products are prescribed for individual patient needs and are not bound to the exact FDA-approved indication language of brand-name drugs, providers in this space sometimes have more flexibility in how they handle continuation cases. That flexibility goes both ways. A careful provider still does a real evaluation of your individual situation rather than rubber-stamping a continuation request. The GLP Winner provider survey helps you compare providers transparently on the pharmacies they work with and the pricing per dose and plan, so you can find a fit that works for your situation.
Verifying that your provider works with a licensed 503A or 503B pharmacy and that the pharmacy is properly credentialed is the right move regardless of which pathway you choose. The 503A vs 503B compounding pharmacies article on GLP Winner walks through how to check.
Documentation to Bring to Your Evaluation
A well-prepared evaluation conversation tends to go faster and produce a better outcome. The following is the kind of information clinicians typically need.
Documentation about your weight and medication history:
- Your starting weight, height, and BMI when you began GLP-1 treatment
- Your current weight, height, and BMI
- The name, dose, and start date of your current or most recent GLP-1 medication
- How long you have been on treatment, including any pauses
Documentation about qualifying conditions:
- Any current or prior diagnoses of type 2 diabetes or prediabetes
- High blood pressure (hypertension)
- High cholesterol (dyslipidemia)
- Cardiovascular disease, including prior heart attack, stroke, or heart failure
- Moderate-to-severe obstructive sleep apnea, if relevant for tirzepatide
- Chronic kidney disease
Documentation about your treatment so far:
- Prior prescriptions or pharmacy records showing your treatment history
- Recent lab work (within the past six to twelve months is generally most useful)
- Any side effects you have experienced and how they were managed
- Notes from any previous providers if you are switching
If you are seeking coverage for an FDA-approved medication through insurance, the following also helps:
- The name of your prescription drug plan
- Your plan’s prior authorization requirements for GLP-1 medications, if you can find them on your plan’s website
- Any prior denials you have received
If you are coming back to treatment after a pause, it helps to bring honesty about that pause: roughly when you stopped, why you stopped, and whether you have noticed any weight coming back or any qualifying conditions returning in the time off the medication. Clinicians can work with the real picture more easily than with a polished one.
What to Do If a Provider Declines
A decline is not necessarily the end of the road. Different clinicians have different practice styles, and different insurance plans have different coverage pathways. A few reasonable next steps:
Get a second opinion. A clinician who specializes in obesity medicine, endocrinology, or cardiology may approach the evaluation differently than a primary care clinician, particularly if maintenance therapy for chronic disease is part of their everyday practice.
Check your insurance plan’s appeals process. Many plans have a formal appeal pathway that allows your clinician to submit additional documentation, especially if you have a qualifying condition that supports continued treatment. The appeal often succeeds when the original denial gets supplemented with clearer documentation of your full picture.
Be patient with the system. Coverage rules are changing, particularly with the Medicare GLP-1 Bridge launching in July 2026 and with private insurance plans updating their formularies year over year. A door that is closed this year may open next year.
Final Takeaway
If you have done the work to lose weight on a GLP-1 medication and you want to keep going, the medical case for continuation is supported by the published research, and the regulatory landscape is steadily moving toward more pathways for coverage, not fewer. The FDA labels define who can start treatment. The clinical decision about who continues belongs with a licensed provider who can look at your full picture, including your weight history, your qualifying conditions, and the real risk of regain if you stop.
The most useful thing you can do is bring a complete, honest picture to your evaluation visit. Your starting numbers, your current numbers, your medical history, your medications, and your treatment history all belong in that conversation. A clinician working with a full picture can advocate for you within the constraints of your insurance, and a thoughtful provider will also be honest with you about what the evidence supports.
Coverage will shift. The Bridge program is one example. New indications and new evidence keep changing what is possible. Your job is to have the conversation, bring the documentation, and find a provider who treats your situation as the individual case it is.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
GLP-1 users are buying more hot sauce & ketchup, and the food industry is moving fast. Here is what the science says about taste changes on GLP-1s.
Wondering about GLP-1s? Here are five basics on candidacy, dosing, food noise, and compounded options to know before your first appointment.
Mood, libido, taste, sleep, hair, and body changes on GLP-1 medications are real, common, and often missed. What the newest research shows.
Categories
Curated by
